SLRN Stock Overview
A clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Acelyrin, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.15 |
| 52 Week High | US$8.89 |
| 52 Week Low | US$3.11 |
| Beta | 0 |
| 1 Month Change | -32.98% |
| 3 Month Change | -35.85% |
| 1 Year Change | -55.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.60% |
Recent News & Updates
Acelyrin: Abandoned Programs Do Not Give Confidence
Dec 09Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Sep 20Recent updates
Shareholder Returns
| SLRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | -3.8% | -2.7% |
| 1Y | -55.8% | -2.6% | 23.4% |
Return vs Industry: SLRN underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: SLRN underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| SLRN volatility | |
|---|---|
| SLRN Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SLRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLRN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 93 | Mina Kim | www.acelyrin.com |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
Acelyrin, Inc. Fundamentals Summary
| SLRN fundamental statistics | |
|---|---|
| Market cap | US$316.03m |
| Earnings (TTM) | -US$264.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs SLRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$264.41m |
| Earnings | -US$264.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 10:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acelyrin, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samantha Lynn Semenkow | Citigroup Inc |
| Emily Bodnar | H.C. Wainwright & Co. |
| Akash Tewari | Jefferies LLC |